6446.Tw
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
Analyst recommendations
10 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
The company maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 6.2, suggesting a robust ability to meet short-term obligations. The company's free cash flow of 3,153,891,000 TWD supports its operational flexibility and potential for reinvestment or shareholder returns.
Profitability metrics show a return on equity of 15.78% and a return on assets of 13.49%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing at or above the industry median in terms of profitability and returns.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn.
Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of -1,923,704,000 TWD indicates a reduction in investment in physical assets, which may reflect a strategic shift or a focus on optimizing existing resources.
The company faces a medium liquidity risk, as noted in its risk assessment, and a low dilution risk, suggesting that the company is not expected to issue additional shares in the near term. The risk assessment also highlights that the company has a negative net cash position after accounting for total debt, which could impact its financial flexibility.
Recent events, as reflected in the company's financial filings, indicate a stable financial position with no major adverse events reported in the latest period. The company's financial health is supported by strong operating cash flow and a solid equity base.
- The company has a strong capital structure with a low debt-to-equity ratio and a high current ratio.
- Profitability metrics are robust, with a return on equity and return on assets that are in line with industry standards.
- The company's revenue is concentrated in a single segment, which may increase its exposure to market-specific risks.
- The company is projected to maintain a stable growth trajectory with no significant changes in revenue expected in the next fiscal year.
- The company faces a medium liquidity risk and a low dilution risk, indicating a stable financial position.
- **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable, supported by its strong operating income and net income.
- **rd_outlook_rationale**: The company's research and development outlook is not explicitly provided, but its capital expenditure suggests a focus on optimizing existing resources.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 22,96 |
| Revenue | —no estimate | —no estimate | 24,2B TWD |
| Operating income | —no estimate | —no estimate | 9,8B TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6446.TW Market data — financials · 2026-05-27
- PharmaEssentia Corp Market data — analyst estimates · 2026-05-27